Equities

Lionco Pharmaceutical Group Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Lionco Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.72
  • Today's Change-0.06 / -1.26%
  • Shares traded4.72m
  • 1 Year change-13.55%
  • Beta0.7843
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lionco Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research, development, production, and sales of prescription chemical drugs. The Company’s main products cover four main categories: parenteral nutrition, anti-infectives, digestive system drugs, and cardiovascular and cerebrovascular drugs. The Company’s main products include Huperzine A for Injection, Cefmetazole Sodium for Injection, Cefuroxime Sodium for Injection, Cefuroxime Sodium for Injection, Alanyl-Glutamine Injection and others. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)430.61m
  • Net income in CNY-118.38m
  • Incorporated2003
  • Employees436.00
  • Location
    Lionco Pharmaceutical Group Co LtdMedicine Valley Industrial ParkNo. 16 Medicine Valley Erheng RoadNational Hi-tech Industrial Dvlpmnt ZneSHANNAN 856000ChinaCHN
  • Phone+86 8 937830999
  • Fax+86 8 937830888
  • Websitehttp://www.lingkang.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GuiZhou YiBai Pharmaceutical Co., Ltd.1.91bn-234.63m3.29bn5.26k--1.37--1.72-0.3003-0.30032.423.030.47641.439.21362,458.80-6.27-0.973-8.33-1.3158.7072.00-13.17-1.651.25-10.110.2733---22.92-8.34-406.79---13.70--
Shanghai Shenqi Pharmactcl Inv Mgt CoLtd1.88bn62.34m3.31bn1.27k54.881.49--1.760.11860.11863.584.370.59814.665.411,487,675.001.85-0.69472.33-0.865644.6053.833.10-1.042.5731.840.0745---12.481.2325.24-3.20-13.91--
Lionco Pharmaceutical Group Co Ltd430.61m-118.38m3.45bn436.00--4.69--8.01-0.1609-0.16090.59281.020.35783.932.41987,638.40-9.84-2.45-11.09-3.1345.8972.39-27.49-9.672.80-2.730.2791--92.95-25.3213.68---4.03--
Shanghai Hile Bio-Technology Co Ltd246.35m171.34m3.52bn366.0018.012.31--14.290.29980.29980.38952.340.14380.83462.49673,097.9011.904.1514.285.6575.2652.8882.7525.096.92--0.010626.1712.59-0.5053172.2869.73-26.4767.20
Shanghai Fudan Forward S&T Co Ltd661.28m-119.02m3.63bn1.41k--5.83--5.49-0.1744-0.17440.97210.91580.42680.80159.29467,663.00-7.83-3.33-14.36-5.8232.0539.99-18.35-7.670.4787-12.630.4378---5.05-14.35-509.42---18.59--
Data as of Feb 11 2026. Currency figures normalised to Lionco Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.10%Per cent of shares held by top holders
HolderShares% Held
Gfund Management Co., Ltd.as of 30 Jun 2025717.20k0.10%
GF Fund Management Co., Ltd.as of 30 Jun 202524.70k0.00%
Bank of Beijing Scotiabank Asset Management Co., Ltd.as of 30 Jun 20255.20k0.00%
Hongde Fund Management Co., Ltd.as of 30 Jun 20251.90k0.00%
Bosera Asset Management Co., Ltd.as of 30 Jun 20250.000.00%
Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.